U.S. Healthcare Sector Analysis

Sector Valuation and Performance

Has the U.S. Healthcare Sector valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Sun, 17 May 2026	US$6.2t	US$3.3t	US$122.3b	22.6x	50.5x	1.9x
Tue, 14 Apr 2026	US$6.2t	US$3.3t	US$127.2b	23.1x	48.8x	1.9x
Thu, 12 Mar 2026	US$6.4t	US$3.3t	US$124.3b	24.9x	51.3x	2x
Sat, 07 Feb 2026	US$6.4t	US$3.3t	US$125.4b	27.1x	51.4x	2x
Mon, 05 Jan 2026	US$6.5t	US$3.2t	US$135.6b	25.7x	47.8x	2x
Wed, 03 Dec 2025	US$6.4t	US$3.2t	US$133.5b	25.7x	47.9x	2x
Fri, 31 Oct 2025	US$6.0t	US$3.1t	US$124.5b	25.8x	48x	1.9x
Sun, 28 Sep 2025	US$5.7t	US$3.1t	US$137.6b	23.6x	41.1x	1.8x
Tue, 26 Aug 2025	US$5.7t	US$3.1t	US$137.2b	23.4x	41.5x	1.8x
Thu, 24 Jul 2025	US$5.5t	US$3.0t	US$128.5b	25.3x	42.7x	1.8x
Sat, 21 Jun 2025	US$5.5t	US$3.0t	US$127.4b	23.7x	42.8x	1.8x
Mon, 19 May 2025	US$5.4t	US$3.0t	US$126.1b	23.3x	42.9x	1.8x
Wed, 16 Apr 2025	US$5.4t	US$2.6t	US$89.8b	25.2x	60x	2x
Fri, 14 Mar 2025	US$5.6t	US$2.6t	US$74.9b	26.1x	75.2x	2.1x
Sun, 09 Feb 2025	US$5.9t	US$2.6t	US$89.8b	26.5x	65.5x	2.2x
Tue, 07 Jan 2025	US$5.8t	US$2.9t	US$79.3b	27.4x	73.3x	2x
Thu, 05 Dec 2024	US$6.1t	US$2.9t	US$77.5b	29.5x	79.2x	2.1x
Sat, 02 Nov 2024	US$6.1t	US$2.9t	US$71.3b	28.4x	85.8x	2.1x
Mon, 30 Sep 2024	US$6.2t	US$2.9t	US$70.6b	30.1x	87.9x	2.1x
Wed, 28 Aug 2024	US$6.3t	US$2.8t	US$56.5b	31.8x	111x	2.2x
Fri, 26 Jul 2024	US$6.4t	US$2.8t	US$61.6b	31.6x	103.4x	2.2x
Sun, 23 Jun 2024	US$6.2t	US$2.8t	US$62.5b	30x	99.2x	2.2x
Tue, 21 May 2024	US$6.2t	US$2.8t	US$64.1b	30.9x	97.2x	2.2x
Thu, 18 Apr 2024	US$5.9t	US$2.8t	US$84.3b	30.5x	70.3x	2.1x
Sat, 16 Mar 2024	US$6.2t	US$2.8t	US$84.5b	31x	73.9x	2.2x
Mon, 12 Feb 2024	US$6.2t	US$2.8t	US$76.3b	31.6x	81x	2.2x
Wed, 10 Jan 2024	US$6.4t	US$2.8t	US$90.1b	31.9x	70.9x	2.3x
Fri, 08 Dec 2023	US$6.0t	US$2.8t	US$91.4b	29x	65.1x	2.1x
Sun, 05 Nov 2023	US$5.7t	US$2.8t	US$88.4b	26.7x	65x	2x
Tue, 03 Oct 2023	US$5.9t	US$2.8t	US$98.2b	26.7x	59.7x	2.1x
Thu, 31 Aug 2023	US$6.1t	US$2.8t	US$98.7b	27.9x	62.2x	2.2x
Sat, 29 Jul 2023	US$6.1t	US$2.8t	US$115.6b	28x	52.5x	2.2x
Mon, 26 Jun 2023	US$6.0t	US$2.7t	US$109.8b	26.6x	54.8x	2.2x
Wed, 24 May 2023	US$5.9t	US$2.7t	US$110.9b	24.4x	53.5x	2.2x

Current Industry PE

Investors are pessimistic on the American Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.

The industry is trading at a PE ratio of 50.5x which is lower than its 3-year average PE of 65.5x.

The 3-year average PS ratio of 2.1x is higher than the industry's current PS ratio of 1.9x.

Past Earnings Growth

The earnings for companies in the Healthcare industry have grown 3.3% per year over the last three years.
Revenues for these companies have grown 7.0% per year.
This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare sector?


US Market	-0.34%
Healthcare	-0.027%
Healthcare Services	2.64%
Pharma	2.02%
Medical Equipment	-1.38%
Biotech	-1.60%
Life Sciences	-5.74%
Healthtech	-8.88%

Industry PE

Investors are most optimistic about the Medical Equipment industry even though it's trading below its 3-year average PE ratio of 54.7x.

Analysts are expecting annual earnings growth of 16.2%, which is higher than its past year's earnings growth of 14.0% per year.

Forecasted Growth

Analysts are most optimistic on the Biotech industry, expecting annual earnings growth of 25% over the next 5 years.
However this is lower than its past earnings growth rate of 43% per year.

In contrast, the Pharma industry is expected to see its earnings grow by 14% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
LLY Eli Lilly	US$1.00k	6.0% +US$50.4b	32.7%	PE35.5x
ABBV AbbVie	US$210.39	4.4% +US$15.6b	14.3%	PE103.4x
JNJ Johnson & Johnson	US$226.71	2.4% +US$13.0b	49.8%	PE25.9x
UNH UnitedHealth Group	US$393.85	3.7% +US$12.6b	34.9%	PE29.7x
SYK Stryker	US$306.76	7.5% +US$8.3b	-22.2%	PE35.2x

Eli Lilly and Company Presents Results for Foundayo and Zepbound in Weight Loss Maintenance Trials

Eli Lilly and Company announced detailed results from two late-phase trials showing that people with obesity maintained their weight loss long term with either Foundayo or lower-dose Zepbound after switching from higher doses of injectable incretin therapy. The findings from SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN, were presented at the 33rd European Congress on Obesity (ECO) and published in The Lancet and Nature Medicine, respectively. In SURMOUNT-MAINTAIN, both Zepbound MTD and Zepbound 5 mg met the primary and all key secondary endpoints, demonstrating weight-loss maintenance after 60-weeks of initial treatment with Zepbound MTD. The primary endpoint was to demonstrate that continuation of Zepbound either at a reduced 5 mg dose or at MTD was superior to placebo in percent change in body weight at week 112. At week 112, participants continuing treatment with Zepbound MTD preserved all of their prior weight loss, while dose reduction to 5 mg maintained all but 5.6 kg on average. ATTAIN-MAINTAIN demonstrated that switching to Foundayo also supported long-term weight maintenance, meeting the primary and all key secondary endpoints using both the efficacy estimand and treatment-regimen estimand. The primary endpoint was to demonstrate that Foundayo was superior to placebo in percent maintenance of body weight reduction, among SURMOUNT-5 participants who previously reached a body weight plateau. At week 52, participants who switched from Wegovy MTD to Foundayo maintained all but 0.9 kg of their previously achieved weight loss, while those who switched from Zepbound MTD to Foundayo maintained all but 5.0 kg. Across both trials, Foundayo and Zepbound demonstrated safety profiles consistent with prior Phase 3 studies. In ATTAIN-MAINTAIN, the most common adverse events with Foundayo vs. placebo were nausea (18.8% vs. 4.1%), constipation (13.1% vs. 4.1%), vomiting (8.3% vs. 3.4%) or diarrhea (7.4% vs. 7.5%). Discontinuation rates due to adverse events for patients randomized to placebo or Foundayo were 4.8% (Foundayo from Wegovy), 7.6% (placebo from Wegovy), 7.2% (Foundayo from Zepbound) and 6.3% (placebo from Zepbound). In SURMOUNT-MAINTAIN, the most common adverse events during the maintenance period with Zepbound MTD and Zepbound 5 mg vs. placebo were diarrhea (7.2% and 4.9% vs. 1.1%), vomiting (6.5% and 0.7% vs. 0%) and nausea (5.8% and 4.2% vs. 2.2%). Discontinuation rates due to adverse events during the maintenance period with Zepbound MTD, Zepbound 5 mg and placebo were 0%, 0.7% and 0%, respectively. Zepbound (tirzepatide) is a once-weekly dual GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist. Zepbound is a single molecule that activates the body's receptors for GIP and GLP-1, which are natural incretin hormones. Both GIP and GLP-1 receptors are found in areas of the human brain important for appetite regulation. Zepbound decreases calorie intake, and the effects are likely mediated by affecting appetite. Studies of tirzepatide in chronic kidney disease (CKD) and in morbidity/mortality in obesity (MMO) are ongoing.Tirzepatide has been approved by the U.S. FDA as Mounjaro for adults with type 2 diabetes to improve glycemic control, and as Zepbound for adults with obesity, or some adults who are overweight and also have at least one weight-related medical problem, to lose weight and keep it off. Additionally, Zepbound is FDA-approved to treat adults with moderate-to-severe obstructive sleep apnea and obesity. Tirzepatide is also approved as Mounjaro in some countries outside the U.S. for adults with type 2 diabetes, obesity or those who are overweight who also have a weight-related comorbid condition. Both Mounjaro and Zepbound should be used in combination with diet and exercise.

U.S. Healthcare Sector Analysis

Sector Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Elevance Health Sees 8% Medicaid Membership Drop for 2026 as State Trends Diverge

HCA Healthcare Prioritizes US$3 Billion Bond Offering and AI Integration as Risks Shift

Waters Surges on Q1 Earnings Beat and Raised 2026 Outlook After BD Acquisition

CVS: Medicare Advantage Turnaround And PBM Clarity Will Shape Future Earnings Profile

We Think You Can Look Beyond AbbVie's (NYSE:ABBV) Lackluster Earnings

Johnson & Johnson Announces Global Launch Of Shockwave C2 Aero Coronary IVL Catheter

UNH: Margin Recovery Hopes Will Clash With Government Program Overhaul Risk

Prime Vendor Contracts And Automation Investments Will Reshape Long Term Earnings Profile

Eli Lilly and Company Presents Results for Foundayo and Zepbound in Weight Loss Maintenance Trials

Thermo Fisher Expands Cell Therapy Manufacturing With New Bioreactor and IBTROZI Drug Production

SYK: Hospital Digitization And Cyber Resilience Will Support 2026 Upside

AMGN: Fair Outlook Weighs Pipeline Execution Against Expanded Manufacturing Commitments

Investor sentiment deteriorates as stock falls 33%

Intuitive Surgical Surpasses Expectations With Robust Q1 Results and Raises Procedure Outlook

First quarter dividend of US$0.40 announced

Investor sentiment improves as stock rises 16%